David Scott Jones - 22 Jun 2021 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
SVP & Chief Commercial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
23 Jun 2021, 17:28:04 UTC
Next filing
03 Nov 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +14,900 +363% $0.000000 19,005 22 Jun 2021 Common Stock 14,900 $0.000000 Direct F1
transaction EYPT Stock Option (Right to Buy) Award $0 +60,300 $0.000000 60,300 22 Jun 2021 Common Stock 60,300 $13.13 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units will vest in three ratable annual installments beginning February 9, 2022.
F2 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.